BIOTON (BIO) Stock Overview
A biotechnology company, develops, manufactures, markets, and sells pharmaceutical ingredient and medicinal products in Poland and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
BIO Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
BIOTON S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł4.10 |
| 52 Week High | zł4.70 |
| 52 Week Low | zł3.37 |
| Beta | 0.26 |
| 1 Month Change | 2.76% |
| 3 Month Change | 2.50% |
| 1 Year Change | 10.81% |
| 3 Year Change | 14.69% |
| 5 Year Change | -21.46% |
| Change since IPO | -96.67% |
Recent News & Updates
Shareholder Returns
| BIO | PL Biotechs | PL Market | |
|---|---|---|---|
| 7D | -5.7% | -2.0% | -3.1% |
| 1Y | 10.8% | -6.5% | 24.6% |
Return vs Industry: BIO exceeded the Polish Biotechs industry which returned -5.9% over the past year.
Return vs Market: BIO underperformed the Polish Market which returned 26.4% over the past year.
Price Volatility
| BIO volatility | |
|---|---|
| BIO Average Weekly Movement | 3.3% |
| Biotechs Industry Average Movement | 6.0% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in PL Market | 11.0% |
| 10% least volatile stocks in PL Market | 3.4% |
Stable Share Price: BIO has not had significant price volatility in the past 3 months compared to the Polish market.
Volatility Over Time: BIO's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 363 | Jeremy Launders | www.bioton.pl |
BIOTON S.A., a biotechnology company, develops, manufactures, markets, and sells pharmaceutical ingredient and medicinal products in Poland and internationally. The company offers recombinant human insulin; oral diabetic drugs; strips for measuring sugar in blood, as well as Gensulin N, Gensulin R, and Gensulin M30; GensuPen 2, an automatic injection system; and GensuCare glucometer, a diabetes monitoring technology, as well as needles. BIOTON S.A. was founded in 1989 and is based in Ozarów Mazowiecki, Poland.
BIOTON S.A. Fundamentals Summary
| BIO fundamental statistics | |
|---|---|
| Market cap | zł352.04m |
| Earnings (TTM) | zł3.39m |
| Revenue (TTM) | zł282.52m |
Is BIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIO income statement (TTM) | |
|---|---|
| Revenue | zł282.52m |
| Cost of Revenue | zł190.72m |
| Gross Profit | zł91.80m |
| Other Expenses | zł88.40m |
| Earnings | zł3.39m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Apr 29, 2026
| Earnings per share (EPS) | 0.04 |
| Gross Margin | 32.49% |
| Net Profit Margin | 1.20% |
| Debt/Equity Ratio | 6.6% |
How did BIO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/05 08:42 |
| End of Day Share Price | 2026/03/05 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BIOTON S.A. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Vladimira Urbankova | Erste Group Bank AG |
| Ovidiu Fer | Wood & Company |